Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia and Transcription Factor Targeting.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ZNF384 drug discovery and fusion-protein oncogene research. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ZNF384 Recombinant Protein (Full-Length & Zinc Finger Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9 Insect Cell / E. coli expressed for structural integrity. |
View ZNF384 Products |
| Gene Delivery | ZNF384 Promise-ORF / Lentivirus Full-length ORF and clinical fusion variants (e.g., TCF3-ZNF384, EP300-ZNF384) for stable cell line generation. |
View ZNF384 Products |
| Benchmark Ab | Anti-ZNF384 Recombinant Antibody Sequence-verified positive control for Western Blot, ChIP, and IP assays. |
View ZNF384 Products |
| Validator | ZNF384 siRNA Set Target-specific knockdown verification in leukemia cell models. |
View ZNF384 Products |
| Related Target A | EP300 Key histone acetyltransferase and common fusion partner of ZNF384 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). |
View EP300 Products |
| Related Target B | CREBBP Transcriptional coactivator frequently fused with ZNF384, driving epigenetic dysregulation in leukemia. |
View CREBBP Products |
| Related Target C | TCF3 Transcription factor E2-alpha, a classical fusion partner (TCF3-ZNF384) implicated in lineage plasticity and lineage switch during immunotherapy. |
View TCF3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zinc Finger Domain Stability | Sf9 Insect Cell expression ensures correct folding and zinc ion coordination, verified by Mass Spectrometry. |
| Fusion Junction Specificity | Custom lentivirus constructs covering precise patient-derived fusion breakpoints (e.g., TCF3-ZNF384, EP300-ZNF384). |
| Lack of Controls | Sequence-verified clinical benchmark recombinant antibodies included for reliable assay baselines. |
| Off-Target Screening | Homolog panels and control siRNA sets included to rule out non-specific transcriptional knockdown. |
Live ZNF384 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of ZNF384-rearranged (ZNF384-r) acute lymphoblastic leukemia is rapidly evolving. Historically classified as a difficult-to-drug transcription factor, ZNF384 is now a major focal point in precision oncology. Because ZNF384-r leukemias exhibit significant lineage plasticity—frequently switching from a lymphoid to a myeloid phenotype under CD19-targeted therapies (such as CAR-T or Blinatumomab)—current R&D is shifting toward targeting the epigenetic machinery associated with ZNF384 fusions. Epigenetic modulators, particularly EP300/CREBBP inhibitors and HDAC inhibitors, represent the next wave of combination therapies designed to bypass resistance and lineage switching.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Epigenetic Inhibitors | Academic Medical Centers, Biotech Startups | ZNF384-r BCP-ALL, Myeloid Leukemia | EP300/CREBBP interaction assays (Requires high-purity recombinant fusion proteins) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Pioneers | Refractory Leukemias | Ubiquitination assays (Requires stable, full-length ZNF384 protein with native post-translational modifications) |
| Multi-targeted Immunotherapy (CAR-T/Bispecifics) | Global Biopharma, Cell Therapy Developers | Lineage-plastic B-ALL | Lineage markers monitoring (Requires CD19/CD22/CD33 validation panels) |